Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928262 | 0.94 | HPGD (0.43) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2932300 | 0.90 | HPGD (0.45) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2924638 | 0.90 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2932783 | 0.89 | HPGD (0.54) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2934550 | 0.83 | HPGD (0.46) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2927215 | 0.83 | HPGD (0.55) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2932129 | 0.80 | HPGD (0.43) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2927267 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL2933104 | 0.79 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2HPGDKDM4E | |
| SCHEMBL5133489 | 0.78 | HPGD (0.43) | NPC1RAB9ASMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| CN-102633783-A | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA INC | 2012-08-15 | — | — | CN | disclosed |
| CN-101379060-B | Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use | TRANSTECH PHARMA INC | 2012-05-23 | — | — | CN | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101379060-A | Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1987028-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| WO-2007095124-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | NPC1 653/4885RAB9A 3858/4885SMN1; SMN2 4734/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | NPC1 653/4885RAB9A 3858/4885SMN1; SMN2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.